News

Article

FDA approves Eyenovia’s Redwood City commercial manufacturing facility

Author(s):

According to a news release, the Redwood City, California, site will complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi.

(Image Credit: AdobeStock/Gorodenkoff)

(Image Credit: AdobeStock/Gorodenkoff)

Eyenovia Inc announced its facility in Redwood City, California successfully completed FDA inspection for approval as a commercial manufacturing facility.

According to a news release from Eyenovia,1 its Redwood City facility will primarily be used for final assembly, packaging, and labeling activities in support of Mydcombi, the first and only fixed combination of tropicamide and phenylephrine for in-office and pre-surgical pupil dilation utilizing Optejet technology.

Michael Rowe, Eyenovia’s CEO, pointed out in the news release the inspection went off without a hitch.

“The FDA inspection of our Redwood City facility was completed efficiently and with no significant concerns raised on the part of the inspector, clearing the way for us to perform final assembly, packaging and labeling in support of a broader U.S. launch of Mydcombi,” Rowe said in the news release. “With Redwood City and Reno now online and operational, we have the capacity to manufacture both commercial product as well as clinical supply in support of our ongoing CHAPERONE clinical trial for pediatric progressive myopia as well as initial testing of other product candidates that leverage our Optejet technology.”

Moreover, Eyenovia noted in its news release the Redwood City site complements its manufacturing capabilities in Reno, as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi in the company’s proprietary Optejet dispensing platform.

“I am very pleased with the results of the audit and commend our manufacturing, engineering, quality and regulatory staff for their diligence and work to make this a reality,” Bren Kern, the company’s COO, added in the news release. “The team had been working tirelessly in preparation for this key milestone and their efforts bore out in the result.”

Reference:
  1. Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility | Eyenovia Inc. Eyenovia Inc. Published 2024. Accessed February 13, 2024. https://ir.eyenovia.com/news-releases/news-release-details/eyenovia-announces-fda-approval-redwood-city-commercial

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.